The BioSciences Group of Fujitsu America, Inc., a worldwide leader in providing innovative and reliable solutions to experimental scientists, today announced a global licensing agreement with GPC Biotech AG, a global cancer drug discovery and development company, for Fujitsu's BioMedCAChe suite of automated docking and molecular modeling software. GPC Biotech will implement BioMedCAChe in its Waltham, Massachusetts and Martinsried/Munich, Germany sites. "We are delighted that GPC Biotech has chosen BioMedCAChe as their docking solution," said Dr. Michael J. McManus, Vice President of the BioSciences Group at Fujitsu America. "Our mission is to develop and provide automated solutions that experimental scientists can use to create powerful simulations right in the laboratory." BioMedCAChe provides powerful tools to speed the drug discovery process by enabling scientists to predict and select better quality leads. Using BioMedCAChe, scientists can view, analyze and modify protein structures using interactive sequence and 3D structure editor windows. In addition, scientists can optimize proteins, dock ligands, and model reactions of molecules with tens of thousands of atoms, all on their desktop computers.